Citius Pharmaceuticals, Inc.
CTXR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001506251
No open-market purchases or sales by Citius Pharmaceuticals, Inc. insiders were filed in the last 90 days; 42 institutions reported holding it in 13F filings for Q2 2026, worth $822.4K in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Citius Pharmaceuticals, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 31 | 34 | +3 |
| Shares | 928.8K | 624.4K | −304.4K (−32.8%) |
| Value | $1.48M | $773.2K | −$703.8K (−47.7%) |
New holders (8)
Institutions that held Citius Pharmaceuticals, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jane Street Group, LLC | 18,885 | $23.4K | 0.00% |
| Simplex Trading, LLC | 9,556 | $11.0K | 0.00% |
| Citigroup Inc | 1,617 | $2.00K | 0.00% |
| Legacy Wealth Managment, LLC | 930 | $1.15K | 0.00% |
| Farther Finance Advisors, LLC | 343 | $425 | 0.00% |
| Quent Capital, LLC | 108 | $134 | 0.00% |
| SRS Capital Advisors, Inc. | 84 | $104 | 0.00% |
| Wells Fargo & Company | 40 | $50 | 0.00% |
Sold out (5)
Institutions that held Citius Pharmaceuticals, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Heights Capital Management, Inc | 159,898 | $254.2K |
| Bay Colony Advisory Group, Inc d/b/a Bay Colony Advisors | 16,500 | $26.2K |
| Group One Trading, L.P. | 649 | $1.03K |
| Raymond James Financial Inc | 226 | $359 |
| Larson Financial Group LLC | 45 | $72 |